A generic version of multiple sclerosis drug Copaxone was introduced in 2015, but it has done little to lower drug costs for MS patients, NPR reported. Yearly costs for MS drugs can run as high as $50 ...

To say that Momenta Pharmaceuticals has been beaten down by Mr. Market in 2014 would be an understatement. The developmental-stage biotech has lost a lot of value since the beginning of the year ...

TEL AVIV, July 14 (Reuters) - There will not be any generic version of Teva Pharmaceutical Industries' multiple sclerosis drug Copaxone before 2014, the company's president and chief executive said in ...

We are lowering our fair value estimate for Teva Pharmaceutical to $10 per share from $11, primarily as a result of our lower top-line forecast over the next two years. The company's first-quarter ...

Read full article: Veteran, civil rights groups want President Biden to give WWI veteran the Medal of Honor Young Men's Leadership Academy celebrating 10 years of success. Here's how to get fabulous ...

NEW YORK--(BUSINESS WIRE)--The overhanging risk of generic competition to Copaxone could prompt material top-line and profit losses at Teva Pharmaceutical Industries Ltd., according to Fitch Ratings.

Shares of Teva Pharmaceutical Industries Ltd. climbed Monday in the first trading day after a federal court reaffirmed patents protecting the drugmaker's biggest brand-name product, the multiple ...

WASHINGTON — Teva Pharmaceutical on Wednesday was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis drug, 10 days before the patent on the medication ...

NEW YORK (AP) -- Teva Pharmaceutical Industries said Monday the federal government is investigating its marketing of its multiple sclerosis drug Copaxone and Parkinson's disease treatment Azilect. The ...

Blue Cross and Blue Shield of Vermont and the Vermont Health Plan filed suit this week against Teva Pharmaceuticals, accusing the company of using some shady tactics to rake in money from its multiple ...

NEW YORK (Reuters) - Momenta Pharmaceuticals Inc said on Friday U.S. regulators had accepted for review its generic version of Teva Pharmaceutical Industries Ltd's multiple sclerosis drug Copaxone, ...